Published in Br J Pharmacol on May 15, 2006
GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell (2010) 8.69
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol (2013) 5.74
Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov (2009) 3.26
GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes (2007) 2.22
Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes (2008) 1.72
The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes (2008) 1.66
Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes (2009) 1.64
Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol Sci (2011) 1.60
Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes (2009) 1.51
The free fatty acid receptor G protein-coupled receptor 40 (GPR40) protects from bone loss through inhibition of osteoclast differentiation. J Biol Chem (2013) 1.49
The G-protein-coupled receptor GPR40 directly mediates long-chain fatty acid-induced secretion of cholecystokinin. Gastroenterology (2010) 1.47
Novel selective ligands for free fatty acid receptors GPR120 and GPR40. Naunyn Schmiedebergs Arch Pharmacol (2009) 1.38
Functional analysis of free fatty acid receptor GPR120 in human eosinophils: implications in metabolic homeostasis. PLoS One (2015) 1.38
Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. J Med Chem (2008) 1.38
G protein-coupled receptors for energy metabolites as new therapeutic targets. Nat Rev Drug Discov (2012) 1.35
Lipid receptors and islet function: therapeutic implications? Diabetes Obes Metab (2009) 1.27
Bidirectional, iterative approach to the structural delineation of the functional "chemoprint" in GPR40 for agonist recognition. J Med Chem (2007) 1.26
The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1. J Biol Chem (2009) 1.21
The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism. Mol Pharmacol (2013) 1.18
Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front Endocrinol (Lausanne) (2012) 1.18
Seven transmembrane G protein-coupled receptor repertoire of gastric ghrelin cells. Mol Metab (2013) 1.14
Differential signaling by splice variants of the human free fatty acid receptor GPR120. Mol Pharmacol (2012) 1.13
AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS One (2011) 1.13
Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469. ACS Med Chem Lett (2010) 1.12
Two arginine-glutamate ionic locks near the extracellular surface of FFAR1 gate receptor activation. J Biol Chem (2008) 1.09
Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells. Diabetologia (2013) 1.09
A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS One (2012) 1.08
Free fatty acid receptors: emerging targets for treatment of diabetes and its complications. Ther Adv Endocrinol Metab (2010) 1.06
Seven transmembrane-spanning receptors for free fatty acids as therapeutic targets for diabetes mellitus: pharmacological, phylogenetic, and drug discovery aspects. J Biol Chem (2008) 1.01
Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol Pharmacol (2012) 1.00
Drug discovery opportunities and challenges at g protein coupled receptors for long chain free Fatty acids. Front Endocrinol (Lausanne) (2012) 0.98
Increased glucose metabolism and glycerolipid formation by fatty acids and GPR40 receptor signaling underlies the fatty acid potentiation of insulin secretion. J Biol Chem (2014) 0.95
Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. Br J Pharmacol (2009) 0.95
GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo. Mol Metab (2014) 0.95
A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. PLoS One (2013) 0.93
Activation of the omega-3 fatty acid receptor GPR120 mediates anti-inflammatory actions in immortalized hypothalamic neurons. J Neuroinflammation (2014) 0.93
Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. J Biol Chem (2013) 0.93
GPR40: good cop, bad cop? Diabetes (2009) 0.92
Omega-3 fatty acids and other FFA4 agonists inhibit growth factor signaling in human prostate cancer cells. J Pharmacol Exp Ther (2014) 0.91
Identifying ligands at orphan GPCRs: current status using structure-based approaches. Br J Pharmacol (2016) 0.90
Treatment of type 2 diabetes by free Fatty Acid receptor agonists. Front Endocrinol (Lausanne) (2014) 0.89
Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes. Diabetes Care (2013) 0.88
Exclusive photorelease of signalling lipids at the plasma membrane. Nat Commun (2015) 0.88
Alteration of the glucagon axis in GPR120 (FFAR4) knockout mice: a role for GPR120 in glucagon secretion. J Biol Chem (2014) 0.88
Therapeutic role and ligands of medium- to long-chain Fatty Acid receptors. Front Endocrinol (Lausanne) (2014) 0.87
Short-chain fatty acid sensing in rat duodenum. J Physiol (2015) 0.86
The molecular basis of ligand interaction at free fatty acid receptor 4 (FFA4/GPR120). J Biol Chem (2014) 0.86
Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats. BMC Pharmacol Toxicol (2013) 0.85
Structural requirements for the cytoprotective actions of mono-unsaturated fatty acids in the pancreatic beta-cell line, BRIN-BD11. Br J Pharmacol (2008) 0.84
Potential roles of GPR120 and its agonists in the management of diabetes. Drug Des Devel Ther (2014) 0.84
Endogenously generated omega-3 fatty acids attenuate vascular inflammation and neointimal hyperplasia by interaction with free fatty acid receptor 4 in mice. J Am Heart Assoc (2015) 0.84
CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients. BMC Pharmacol Toxicol (2014) 0.83
Hypothalamic GPR40 signaling activated by free long chain fatty acids suppresses CFA-induced inflammatory chronic pain. PLoS One (2013) 0.83
Minireview: The effects of species ortholog and SNP variation on receptors for free fatty acids. Mol Endocrinol (2013) 0.83
Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4. Br J Pharmacol (2015) 0.83
Drugs or diet?--Developing novel therapeutic strategies targeting the free fatty acid family of GPCRs. Br J Pharmacol (2013) 0.83
G protein-coupled receptors and insulin secretion: 119 and counting. Endocrinology (2007) 0.82
Omega-3 Fatty Acids and FFAR4. Front Endocrinol (Lausanne) (2014) 0.82
FFA1-selective agonistic activity based on docking simulation using FFA1 and GPR120 homology models. Br J Pharmacol (2013) 0.80
Mercaptoacetate and fatty acids exert direct and antagonistic effects on nodose neurons via GPR40 fatty acid receptors. Am J Physiol Regul Integr Comp Physiol (2014) 0.80
Omega-3 fatty acids induce Ca(2+) mobilization responses in human colon epithelial cell lines endogenously expressing FFA4. Acta Pharmacol Sin (2015) 0.79
Differential Gene Expression in GPR40-Overexpressing Pancreatic β-cells Treated with Linoleic Acid. Korean J Physiol Pharmacol (2015) 0.79
Simvastatin Impairs Insulin Secretion by Multiple Mechanisms in MIN6 Cells. PLoS One (2015) 0.79
The role of omega-3 fatty acid receptor GPR120 in insulin resistance. Int J Obes Suppl (2014) 0.77
Mercaptoacetate blocks fatty acid-induced GLP-1 secretion in male rats by directly antagonizing GPR40 fatty acid receptors. Am J Physiol Regul Integr Comp Physiol (2016) 0.77
In vitro and mouse in vivo characterization of the potent free fatty acid 1 receptor agonist TUG-469. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.77
Attenuation of inflammatory and neuropathic pain behaviors in mice through activation of free fatty acid receptor GPR40. Mol Pain (2015) 0.77
Linoleic acid stimulates [Ca2+]i increase in rat pancreatic beta-cells through both membrane receptor- and intracellular metabolite-mediated pathways. PLoS One (2013) 0.77
Docosahexaenoic acid, G protein-coupled receptors, and melanoma: is G protein-coupled receptor 40 a potential therapeutic target? J Surg Res (2014) 0.77
Cloning, identification and functional characterization of bovine free fatty acid receptor-1 (FFAR1/GPR40) in neutrophils. PLoS One (2015) 0.76
PPARγ signaling and emerging opportunities for improved therapeutics. Pharmacol Res (2016) 0.76
Long-chain unsaturated fatty acids reduce the transcriptional activity of the rat follicle-stimulating hormone β-subunit gene. J Reprod Dev (2016) 0.76
GPR40/FFA1 and neutral sphingomyelinase are involved in palmitate-boosted inflammatory response of microvascular endothelial cells to LPS. Atherosclerosis (2015) 0.76
Free fatty acid receptors: structural models and elucidation of ligand binding interactions. BMC Struct Biol (2015) 0.76
Differential intracellular calcium influx, nitric oxide production, ICAM-1 and IL8 expression in primary bovine endothelial cells exposed to nonesterified fatty acids. BMC Vet Res (2016) 0.76
Polyunsaturated fatty acid receptors, GPR40 and GPR120, are expressed in the hypothalamus and control energy homeostasis and inflammation. J Neuroinflammation (2017) 0.75
Medium-chain fatty acids modulate myocardial function via a cardiac odorant receptor. Basic Res Cardiol (2017) 0.75
Novel identification of the free fatty acid receptor FFAR1 that promotes contraction in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol (2015) 0.75
A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes. Pharmacol Res Perspect (2016) 0.75
Discovery of the First Environment-Sensitive Fluorescent Probe for GPR120 (FFA4) Imaging. ACS Med Chem Lett (2017) 0.75
Deletion of GPR40 fatty acid receptor gene in mice blocks mercaptoacetate-induced feeding. Am J Physiol Regul Integr Comp Physiol (2016) 0.75
Arachidonic acid triggers [Ca2+]i increases in rat round spermatids by a likely GPR activation, ERK signalling and ER/acidic compartments Ca2+ release. PLoS One (2017) 0.75
Dietary polyunsaturated fatty acids and their metabolites: Implications for diabetes pathophysiology, prevention, and treatment. Nutr Healthy Aging (2017) 0.75
Activation of GPR40 attenuates chronic inflammation induced impact on pancreatic β-cells health and function. BMC Cell Biol (2014) 0.75
Comparative effects of the ω3 polyunsaturated fatty acid derivatives resolvins E1 and D1 and protectin DX in models of inflammation and pain. J Inflamm Res (2017) 0.75
Chylomicrons stimulate incretin secretion in mouse and human cells. Diabetologia (2017) 0.75
Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci (1983) 6.89
Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature (2003) 6.87
Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology (1990) 6.34
Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med (2004) 6.16
The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem (2002) 5.53
Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem (2003) 4.79
Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci U S A (1992) 4.38
The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem (2002) 4.11
The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab (2005) 2.71
Malonyl-CoA and long chain acyl-CoA esters as metabolic coupling factors in nutrient-induced insulin secretion. J Biol Chem (1992) 2.66
Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem Biophys Res Commun (2003) 2.52
Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190,562 genetic variations in the human genome. Single-nucleotide polymorphism. J Hum Genet (2002) 2.11
Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta (2002) 2.10
A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem Biophys Res Commun (2003) 2.03
Reduction in voltage-gated K+ currents in primary cultured rat pancreatic beta-cells by linoleic acids. Endocrinology (2005) 2.00
Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol (1988) 1.91
The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. J Clin Invest (1997) 1.89
Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism (2001) 1.87
Role of GPR40 in fatty acid action on the beta cell line INS-1E. Biochem Biophys Res Commun (2005) 1.69
A role for malonyl-CoA in glucose-stimulated insulin secretion from clonal pancreatic beta-cells. J Biol Chem (1989) 1.67
Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells. Biochem J (2003) 1.58
Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet beta-cells: mediation by PLC and L-type Ca2+ channel and link to insulin release. Am J Physiol Endocrinol Metab (2005) 1.55
A cluster of four novel human G protein-coupled receptor genes occurring in close proximity to CD22 gene on chromosome 19q13.1. Biochem Biophys Res Commun (1997) 1.50
Mechanisms of the stimulation of insulin release by saturated fatty acids. A study of palmitate effects in mouse beta-cells. Diabetes (1994) 1.44
Free fatty acid receptor 1 (FFA(1)R/GPR40) and its involvement in fatty-acid-stimulated insulin secretion. Cell Tissue Res (2005) 1.36
A family of fatty acid binding receptors. DNA Cell Biol (2005) 1.25
Quantitative trait linkage analysis of lipid-related traits in familial type 2 diabetes: evidence for linkage of triglyceride levels to chromosome 19q. Diabetes (2002) 1.21
Palmitate increases L-type Ca2+ currents and the size of the readily releasable granule pool in mouse pancreatic beta-cells. J Physiol (2004) 1.20
Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. Diabetes (1998) 1.19
Acute effects of fatty acids on insulin secretion from rat and human islets of Langerhans. J Endocrinol (2002) 1.09
Signal transduction mechanisms in nutrient-induced insulin secretion. Diabetologia (1997) 1.07
A fatty acid- dependent step is critically important for both glucose- and non-glucose-stimulated insulin secretion. J Clin Invest (1998) 1.01
Glibenclamide inhibits islet carnitine palmitoyltransferase 1 activity, leading to PKC-dependent insulin exocytosis. Am J Physiol Endocrinol Metab (2003) 0.97
Palmitate-induced Ca2+-signaling in pancreatic beta-cells. Mol Cell Endocrinol (2003) 0.97
Studies of relationships between variation of the human G protein-coupled receptor 40 Gene and Type 2 diabetes and insulin release. Diabet Med (2005) 0.95
GPR40 gene Arg211His polymorphism may contribute to the variation of insulin secretory capacity in Japanese men. Metabolism (2005) 0.95
Heterologous expression of G protein-coupled receptors in U-2 OS osteosarcoma cells. Receptors Channels (2004) 0.92
The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem (2002) 5.53
The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem (2002) 4.11
Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem (2003) 2.52
The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol (2005) 2.16
Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). J Med Chem (2002) 1.94
Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther (2006) 1.37
Synthesis and activity of small molecule GPR40 agonists. Bioorg Med Chem Lett (2006) 1.12
Identification of a histamine H4 receptor on human eosinophils--role in eosinophil chemotaxis. J Recept Signal Transduct Res (2002) 1.11
Synthesis and evaluation of novel heterocyclic inhibitors of GSK-3. Bioorg Med Chem Lett (2006) 1.11
Postcode lotteries in public health--the NHS Health Checks Programme in North West London. BMC Public Health (2011) 1.08
Regulation of ingestive behaviors in the rat by GSK1521498, a novel micro-opioid receptor-selective inverse agonist. J Pharmacol Exp Ther (2011) 1.07
Refining efficacy: allosterism and bias in G protein-coupled receptor signaling. Methods Mol Biol (2011) 1.03
The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property? Mol Pharmacol (2008) 1.01
Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonist. J Clin Pharmacol (2011) 0.98
Gene expression and immunolocalization of 15-lipoxygenase isozymes in the airway mucosa of smokers with chronic bronchitis. Am J Respir Cell Mol Biol (2002) 0.93
Amine substituted N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-tetrahydro-8-quinolinamines as CXCR4 antagonists with potent activity against HIV-1. Bioorg Med Chem Lett (2009) 0.92
Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4. Chem Biol Drug Des (2006) 0.92
Solid phase synthesis and SAR of small molecule agonists for the GPR40 receptor. Bioorg Med Chem Lett (2007) 0.92
Discovery of small molecule agonists for the bombesin receptor subtype 3 (BRS-3) based on an omeprazole lead. Bioorg Med Chem Lett (2008) 0.90
Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent anti-HIV activity. Bioorg Med Chem Lett (2010) 0.87
The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems. Br J Pharmacol (2006) 0.87
Identification of small molecule agonists of the motilin receptor. Bioorg Med Chem Lett (2008) 0.87
Regulation of TNF-alpha secretion by a specific melanocortin-1 receptor peptide agonist. Peptides (2003) 0.86
Potent, selective, and orally efficacious antagonists of melanin-concentrating hormone receptor 1. J Med Chem (2006) 0.86
A coding polymorphism in the CYSLT2 receptor with reduced affinity to LTD4 is associated with asthma. Pharmacogenetics (2004) 0.86
Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors. Bioorg Med Chem Lett (2008) 0.85
Hepatitis C replication inhibitors that target the viral NS4B protein. J Med Chem (2013) 0.83
Lysosomes contribute to anomalous pharmacokinetic behavior of melanocortin-4 receptor agonists. Pharm Res (2007) 0.82
Optimized procedures for producing biologically active chemokines. Protein Expr Purif (2009) 0.82
Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacology (Berl) (2005) 0.80
Oxazolidinones as novel human CCR8 antagonists. Bioorg Med Chem Lett (2006) 0.80
Rapid expression of recombinant proteins in modified CHO cells using the baculovirus system. Cytotechnology (2002) 0.79
2,5-Disubstituted pyridines as potent GPR119 agonists. Bioorg Med Chem Lett (2010) 0.79
Synthesis of a novel tricyclic 1,2,3,4,4a,5,6,10b-octahydro-1,10-phenanthroline ring system and CXCR4 antagonists with potent activity against HIV-1. Bioorg Med Chem Lett (2010) 0.78
Development of a novel high-throughput surrogate assay to measure HIV envelope/CCR5/CD4-mediated viral/cell fusion using BacMam baculovirus technology. J Biomol Screen (2003) 0.78
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase. J Med Chem (2013) 0.78
Imidazopyridine-5,6,7,8-tetrahydro-8-quinolinamine derivatives with potent activity against HIV-1. Bioorg Med Chem Lett (2009) 0.77
6-(4-chlorophenyl)-3-substituted-thieno[3,2-d]pyrimidin-4(3H)-one-based melanin-concentrating hormone receptor 1 antagonist. J Med Chem (2006) 0.77
The discovery and optimization of pyrimidinone-containing MCH R1 antagonists. Bioorg Med Chem Lett (2006) 0.76
New eyes to see texture in ligand efficacy. Nat Methods (2005) 0.76
Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate. Bioorg Med Chem Lett (2010) 0.76
Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents. Bioorg Med Chem Lett (2010) 0.76
Novel benzimidazole-based MCH R1 antagonists. Bioorg Med Chem Lett (2006) 0.76
The secret lives of GPCRs. Drug Discov Today (2003) 0.76
A concise synthesis of 1,4-dihydro-[1,4]diazepine-5,7-dione, a novel 7-TM receptor ligand core structure with melanocortin receptor agonist activity. Bioorg Med Chem (2010) 0.75
Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy. Bioorg Med Chem Lett (2008) 0.75
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues. Bioorg Med Chem Lett (2008) 0.75
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups. Bioorg Med Chem Lett (2008) 0.75
Tetrahydroquinoline derivatives as opioid receptor antagonists. Bioorg Med Chem Lett (2010) 0.75
Journal of Receptors and Signal Transduction. Editorial. J Recept Signal Transduct Res (2010) 0.75
Characterization of melanocortin receptors. Curr Protoc Pharmacol (2003) 0.75
Application of X-ray photoelectron spectroscopy in determining the structure of solid-phase bound substrates. J Comb Chem (2002) 0.75